activity Committee Member, Data Safety Monitoring Committee for Protocol ITL-2002-CL-001 entitled “Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)
01/28/2023 - Presentactivity Board Member, Virtual Medical Advisory Board
03/02/2021 - Presentactivity Board Member, Systemic Mastocytosis Advisory Board
07/17/2020 - Presentactivity Board Member, HAE Virtual Advisory Board,
07/25/2020 - Presentactivity Board Member, Advances in Hereditary Angioedema (HAE) Prophylaxis Advisory Board
06/22/2019 - Presentactivity Board Member, Lanadelumab Virtual Advisory Board
04/24/2018 - Presentactivity Board Member, HAE Scientific Advisory Board
04/08/2017 - Presentactivity Reviewer
2016 - Presentactivity Reviewer
2010 - Presentactivity Member
2018 - PresentDescriptionTraining Program Director Assemblyactivity Member
2010 - PresentDescriptionElected to Fellowship in March 2010activity Committee Member
2016 - Presentactivity Chair
2018 - Presentactivity Board of Directors
2019 - PresentDescription(Registration Chair 2019-2020, 2021-present)activity Member
2021 - Presentactivity “Approach to Aspirin/NSAID Drug Allergy”
activity Committee Member
2021 - 2022activity Member, COVID-19 Vaccine Clinical Advisory Group
2021 - 2022activity “Advances in the Clinical Management of Hereditary Angioedema”
activity “Recognition and Management of Aspirin Exacerbated Respiratory Disease (AERD)”